Chief Medical Officers (United Kingdom)

ACTIVE HEALTH FOODS, INC. ADDS RESPECTED MEDICAL DOCTORS TO BOARD OF DIRECTORS

Retrieved on: 
Wednesday, June 22, 2022
American Academy, Chief Medical Officers (United Kingdom), Health care, Chris Hani Baragwanath Hospital, Bioidentical hormone replacement therapy, Company, OTC, BIO, Senior management, Medicine, Ownership, GLOBE, University, IHS, CA, Wilderness Medical Society, Anti-aging movement, University of the Witwatersrand, Doctor of Medicine, Telehealth, American Association of Clinical Endocrinologists, BHRT, Patient, Board of directors, Board, Physician, Woman, Luc, Alternative medicine, Management, Pharmaceutical industry, Director

Dr. Thierry Hertoghe, based in Brussels, Belgium, has joined BIO as the Chairman of its Scientific Board of Directors.

Key Points: 
  • Dr. Thierry Hertoghe, based in Brussels, Belgium, has joined BIO as the Chairman of its Scientific Board of Directors.
  • Both of these highly respected Medical Doctors are also substantial shareholders in the Company, representing 22% ownership collectively.
  • www.hertoghemedicalschool.eu
    Joe Wallace, AHFDs President stated, The participation of these highly respected Anti-Aging Medical Doctors in guiding the Active Health business plan as it expands around the world, is invaluable.
  • AHFD will be announcing the other members of its Scientific Board and Board of Directors during the next week.

SIRTLab Corporation Appoints Michael G. Kauffman, MD, PhD, as Co-Chairman of the Board of Directors and Chief Medical Officer

Retrieved on: 
Wednesday, June 22, 2022
Doctor of Philosophy, Harvard University, Liver disease, Internal medicine, Carfilzomib, Rheumatology, Institute of Liver and Biliary Sciences, Inflammation, Harvard Medical School, Technology, Johns Hopkins School of Medicine, Chief Medical Officers (United Kingdom), Glucose, Lipid metabolism, Epix Pharmaceuticals, Director, CEO, Takeda Oncology, Research, Gene expression, Chronic liver disease, Beth Israel Hospital, Company, Sirtuin 6, Biotechnology, SIRT6, Lipid, Metabolic syndrome, Massachusetts General Hospital, Bar-Ilan University, MD, Fatty liver disease, CMO, Research and development, NASH, Patient, Board, Longevity, NF-κB, Multimedia, The Co Founder, Mouse, Liver, Glycolysis, Management, Pharmaceutical industry, Biogen

Dr. Kauffman joins Boaz Misholi, Founder and Co-Chairman; Professor Haim Cohen, Founder and Chief Scientist; Hagit Ashush, PhD, Vice President, Research and Development; and Amir Shukrun, Chief Financial Officer.

Key Points: 
  • Dr. Kauffman joins Boaz Misholi, Founder and Co-Chairman; Professor Haim Cohen, Founder and Chief Scientist; Hagit Ashush, PhD, Vice President, Research and Development; and Amir Shukrun, Chief Financial Officer.
  • Dr. Kauffman's appointment follows positive proof of concept preclinical data in non-alcoholic steatohepatitis (NASH) and longevity models.
  • SIRT6 suppresses triglyceride synthesis, fat metabolism and inflammation (by suppression of NF-kB and other pathways), as well as glycolysis.
  • SIRTLab Corporation is a privately held liver diseases and longevity company headquartered in the Rehovot Science Park, Israel.

SIRTLab Corporation Appoints Michael G. Kauffman, MD, PhD, as Co-Chairman of the Board of Directors and Chief Medical Officer

Retrieved on: 
Wednesday, June 22, 2022
Doctor of Philosophy, Harvard University, Liver disease, Internal medicine, Carfilzomib, Rheumatology, Institute of Liver and Biliary Sciences, Inflammation, Harvard Medical School, Technology, Johns Hopkins School of Medicine, Chief Medical Officers (United Kingdom), Glucose, Lipid metabolism, Epix Pharmaceuticals, Director, CEO, Takeda Oncology, Research, Gene expression, Chronic liver disease, Beth Israel Hospital, Company, Sirtuin 6, Biotechnology, SIRT6, Lipid, Metabolic syndrome, Massachusetts General Hospital, Bar-Ilan University, MD, Fatty liver disease, CMO, Research and development, NASH, Patient, Board, Longevity, NF-κB, The Co Founder, Mouse, Liver, Glycolysis, Pharmaceutical industry, Biogen

Dr. Kauffman joins Boaz Misholi, Founder and Co-Chairman; Professor Haim Cohen, Founder and Chief Scientist; Hagit Ashush, PhD, Vice President, Research and Development; and Amir Shukrun, Chief Financial Officer.

Key Points: 
  • Dr. Kauffman joins Boaz Misholi, Founder and Co-Chairman; Professor Haim Cohen, Founder and Chief Scientist; Hagit Ashush, PhD, Vice President, Research and Development; and Amir Shukrun, Chief Financial Officer.
  • Dr. Kauffman's appointment follows positive proof of concept preclinical data in non-alcoholic steatohepatitis (NASH) and longevity models.
  • SIRT6 suppresses triglyceride synthesis, fat metabolism and inflammation (by suppression of NF-kB and other pathways), as well as glycolysis.
  • SIRTLab Corporation is a privately held liver diseases and longevity company headquartered in the Rehovot Science Park, Israel.

OVME Medical Aesthetics Announces Kevin Keith as Chief Marketing Officer 

Retrieved on: 
Tuesday, May 24, 2022
Cosmetics, Men, Retail, Health, Consumer, Luxury, Other Communications, Marketing, Advertising, General Health, Other Consumer, Communications, Specialty, Women, Coca-Cola, City, Creativity, Forbes, Multimedia, Woman, Orangetheory Fitness, ANA, Chief Medical Officers (United Kingdom), Mercedes-Benz, Citibank, Marketing, Hotel manager, National Association Medical Staff Services, Culture, Facebook, Instagram, Man, UPS, Technology, Advertising, Acquisition, Little Black Book, Growth, Sales

Renowned national medical aesthetics enterprise OVME (pronounced of me), which is backed by VMG Partners, announces the hire of Kevin Keith as Chief Marketing Officer to its Executive Leadership Team.

Key Points: 
  • Renowned national medical aesthetics enterprise OVME (pronounced of me), which is backed by VMG Partners, announces the hire of Kevin Keith as Chief Marketing Officer to its Executive Leadership Team.
  • View the full release here: https://www.businesswire.com/news/home/20220524005086/en/
    Kevin Keith, OVME Chief Marketing Officer (Photo: Business Wire)
    In this new role, Keith will be responsible for scaling and significantly growing all lines of revenue for OVME's retail studios and e-commerce platform.
  • Working closely with OVMEs Founder and Chief Medical Officer, Dr. S. Mark McKenna, Keith will be an integral member of OVME's Executive Team.
  • Since its opening in 2017, by founder and chief medical officer Dr. S. Mark McKenna, the high-profile medical aesthetics enterprise has garnered a following and reputation as a pioneer in the medical aesthetics category for its luxury treatments, expertly trained medical staff, tech-enabled approach, and self-love mantra.

Dr. Brandee Pappalardo Joins Fresenius Kabi as Chief Medical Officer for North America

Retrieved on: 
Wednesday, May 18, 2022
Medical Supplies, Medical Devices, Health, Hospitals, Other Health, Pharmaceutical, Medical Affairs Bureau, Public health, University of California, Berkeley, HCV, Duke University, Dermatology, Multimedia, Patient, Biology, AbbVie, Goal, North Carolina State University, Chief Medical Officers (United Kingdom), Research, Gastroenterology, Time, Rheumatology, University, HIV, Brandie, Fresenius (company), CEO, Management, Medical device, Immunology

has joined the company as senior vice president and Chief Medical Officer for North America.

Key Points: 
  • has joined the company as senior vice president and Chief Medical Officer for North America.
  • Dr. Pappalardo reports to John Ducker, president and CEO of Fresenius Kabi in North America and is a member of the companys North America executive committee.
  • View the full release here: https://www.businesswire.com/news/home/20220518005330/en/
    Dr. Brandee Pappalardo, senior vice president and Chief Medical Officer at Fresenius Kabi.
  • Im very pleased to welcome Brandee to our leadership team at a time when Fresenius Kabi is rapidly expanding its portfolio and customer base in North America, Ducker said.

Cognoa to Present and Exhibit at the 2021 American Academy of Pediatrics (AAP) National Conference and Exhibition

Retrieved on: 
Friday, October 8, 2021
FAAP, Autism, CDT, Conference, Physician, Use, Diagnosis, PALO, FDA, American Academy of Pediatrics, AAP, Exhibition, American Academy, Intelligence, Chief Medical Officers (United Kingdom), Medical device

PALO ALTO, Calif., Oct. 8, 2021 /PRNewswire/ -- Cognoa , a pediatric behavioral health company developing diagnostic and therapeutic solutions for children living with behavioral health conditions, today announced it will be presenting and exhibiting at the 2021 American Academy of Pediatrics (AAP) Annual National Conference and Exhibition , which will be held virtually October 8 11, 2021.

Key Points: 
  • PALO ALTO, Calif., Oct. 8, 2021 /PRNewswire/ -- Cognoa , a pediatric behavioral health company developing diagnostic and therapeutic solutions for children living with behavioral health conditions, today announced it will be presenting and exhibiting at the 2021 American Academy of Pediatrics (AAP) Annual National Conference and Exhibition , which will be held virtually October 8 11, 2021.
  • Cognoa will showcase Canvas Dx , an AI-based diagnosis aid designed to help physicians diagnose autism in the primary care setting and the first diagnosis aid for autism authorized for commercialization by the FDA.
  • Cognoa will begin making Canvas Dx available by prescription in the U.S. in the coming weeks.
  • Available to registered attendees, sessions relevant to the diagnosis of autism and the current and potential future use of artificial intelligence in pediatric practice at the 2021 AAP National Conference and Exhibition include:

Stephen Hahn, M.D., former U.S. FDA Commissioner, joins YourBio Health as interim Chief Medical Officer

Retrieved on: 
Thursday, September 9, 2021

BOSTON, Sept. 9, 2021 /PRNewswire/ -- YourBio Health, Inc., developers of the world's first painless push-button blood collection device, announced today that Stephen Hahn, M.D. joins as interim Chief Medical Officer; he also serves as the Chief Medical Officer, for the Preemptive Medicine and Health Security initiative at Flagship Pioneering at-large. Dr. Hahn previously served as the U.S. Food and Drug Administration Commissioner from 2019–2021.

Key Points: 
  • joins as interim Chief Medical Officer; healso serves as the Chief Medical Officer, for the Preemptive Medicine and Health Security initiative at Flagship Pioneering at-large.
  • Prior to joining the FDA, he served as Chief Medical Executive at the world-renowned MD Anderson Cancer Center in Houston.
  • In 2017, he was named Deputy President and Chief Operating Officer and was responsible for the day-to-day operations of the Cancer Center.
  • as interim Chief Medical Officer," said Harry Wilcox, Executive Chairmanof YourBio Health.

Stephen Hahn, M.D., former U.S. FDA Commissioner, joins YourBio Health as interim Chief Medical Officer

Retrieved on: 
Thursday, September 9, 2021

BOSTON, Sept. 9, 2021 /PRNewswire/ -- YourBio Health, Inc., developers of the world's first painless push-button blood collection device, announced today that Stephen Hahn, M.D. joins as interim Chief Medical Officer; he also serves as the Chief Medical Officer, for the Preemptive Medicine and Health Security initiative at Flagship Pioneering at-large. Dr. Hahn previously served as the U.S. Food and Drug Administration Commissioner from 2019–2021.

Key Points: 
  • joins as interim Chief Medical Officer; healso serves as the Chief Medical Officer, for the Preemptive Medicine and Health Security initiative at Flagship Pioneering at-large.
  • Prior to joining the FDA, he served as Chief Medical Executive at the world-renowned MD Anderson Cancer Center in Houston.
  • In 2017, he was named Deputy President and Chief Operating Officer and was responsible for the day-to-day operations of the Cancer Center.
  • as interim Chief Medical Officer," said Harry Wilcox, Executive Chairmanof YourBio Health.